Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. - Wikidata - wikimedia - TriplyDB

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

http://www.wikidata.org/entity/Q33369363

about

Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Ixabepilone for the treatment of solid tumors: a review of clinical data Novel non-AR therapeutic targets in castrate resistant prostate cancer Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consort Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.Update on options for treatment of metastatic castration-resistant prostate cancer Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.Therapies in development for castrate-resistant prostate cancer.Novel microtubule-targeting agents - the epothilones.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Castration-resistant prostate cancer: new science and therapeutic prospects.Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.The epothilones: new therapeutic agents for castration-resistant prostate cancer.Castration-resistant prostate cancer: mechanisms, targets, and treatment.Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.Epothilones in the treatment of cancer.Management of prostate cancer. Part 3: metastatic disease.Systemic chemotherapy options for metastatic bladder cancer.New molecular targets in advanced prostate cancer.Novel agents and targets in managing patients with metastatic prostate cancer.Development of new cancer therapeutic agents targeting mitosis.Novel therapies in genitourinary cancer: an update.Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.Novel therapeutic strategies in development for prostate cancer.Current management of prostate cancer: dilemmas and trials Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors Prostate cancer chemotherapy in the era of targeted therapy.Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.The epothilones: how pharmacology relates to clinical utility.Emerging drugs for prostate cancer.

P2860

Q27010542-BF229108-942C-433A-9B4B-09DB67A1F3C7 Q28271570-DB27A458-567F-4DAB-93CE-7DDA73EB55DF Q28383663-0F0460FB-5978-4B91-AF9F-9B700959E5B5 Q33380465-2DF90C32-6A1B-4164-8193-31C642000760 Q33384027-455E4B3E-0611-41AB-B9FB-C8574EA8946C Q33400047-9868040F-9947-41CA-858C-EB5B8EA74C52 Q33526311-043930CC-D2D2-4D84-86BE-1E2A8E59D55A Q33956051-652EB4BC-48E4-42A7-899B-7C2CD1EDECC2 Q33999018-2D59DBE6-9B3C-48DF-9387-29E44D23DE87 Q34180965-74435293-DA21-42DE-9118-CD292C876145 Q34309132-41A783D4-2A66-422B-AEFF-5FF8248153F8 Q34588402-470F80FC-CAD6-4AAA-8378-23F30DC84254 Q34611212-C5FC23A3-13B3-458A-98C7-7B977C973531 Q34611801-F99B0CD4-A1B1-425D-8F5C-ECFAA92E03C0 Q35076264-684D48A3-B071-4089-81C8-E1E97B027635 Q35076330-93FB49FA-3EE9-4E00-AED6-CD7C4FF6619F Q35584399-1F3434DF-BD75-46FB-B0AA-6192DD318B31 Q35864027-3E8587CF-7033-4D95-B741-7DF1705D6C29 Q35945262-B6044579-CAD8-4E03-9994-CA3BA03A86F1 Q36184242-7236501C-5703-4DB2-A096-BFDDA73A1871 Q36241242-3E11B53B-880C-4349-8441-CF70E24DA338 Q36275405-1C646B56-3064-475E-B0CD-3BF6B1EB2664 Q36334889-7B7FD05F-EFFD-4748-973F-CE056B30D1D2 Q36491842-7CA2F0A7-0D4A-4DC8-B50A-3198F1DAB292 Q36499259-BDDF2646-B737-43C7-A3DC-A91925D6CF08 Q36500537-3833C200-0959-4E59-A01A-4D7152FA65D3 Q36532080-EC6BB5E8-E194-483D-8A48-E22FAEA61056 Q36555662-D1BB049B-CD89-49A7-B2B5-6E09C9C88D41 Q36623076-3277BBCF-1022-49E8-AAC4-9B43C3911FF7 Q36856612-B6515032-5ADF-409C-9AB9-FCE178CEA706 Q36988082-A04F2C36-64B0-4707-B27B-8FA71B3AB74E Q37038977-81F3AC15-A871-4BD1-8365-F9C1D5D13309 Q37102535-3AAB5A9D-09BA-4D4F-9712-7D5841C7EB7D Q37104791-440ADB60-0B7D-4C70-83A1-930F0CB7BEC6 Q37180864-98261A0E-F302-4142-B9B8-83828E3B384A Q37255452-89ABE0DB-EEC5-43F8-9866-AE73AB25CC31 Q37290709-A558F3BB-71CD-4AF0-8F17-94DCF09EF4B2 Q37378233-06809785-8EEE-4E06-A839-D11E101AAE68 Q37543912-5FC4C14F-08DB-4278-A59A-52E2EC2E9C0A Q37570555-324BB161-895F-4775-9068-2346271933A1

P2860

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

http://www.wikidata.org/entity/Q33369363

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@ast

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@en

type

label

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@ast

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@en

prefLabel

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@ast

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@en

P1433

Q33369363-74199850-92E6-42BD-811E-E76E810427A4

P1476

Q33369363-C3504E79-D67C-4302-B30D-8B34475B343C

P2093

Q33369363-352FDDF8-92EC-4F03-BAA2-E3F7538C7E3D

Q33369363-43472F8B-536B-459D-BBC3-3E1475ED3F6E

Q33369363-735E7EE4-8BE9-4AA2-B248-34229AD9FB8F

Q33369363-9A484E2A-C59E-4338-8602-239920B6544E

Q33369363-A3B10B12-C7B8-4026-8549-0B39297BF658

Q33369363-A428236D-A0AC-4522-8656-FBAE9087E2CB

Q33369363-A82530F7-9558-4324-82B9-9268EBEAA52E

Q33369363-F35ADBFC-00B2-41D2-AF01-937B07E2302E

P304

Q33369363-4C9C92AD-3A60-423E-8724-B091D2D111D2

P31

Q33369363-3E711498-9A9E-4254-9969-E2F229E824EC

P356

Q33369363-7FC67373-CE94-4A2A-ABD7-061C21FB8088

P407

Q33369363-3F790B4E-E9C3-477D-9D10-828DBCA69964

P433

Q33369363-F8DB78EF-E774-4FC3-A798-98B90971DAAD

P478

Q33369363-91E04563-1A13-4BAA-839E-DF3C04B21D44

P50

Q33369363-7A45A50C-A0B6-43B8-B313-E549B9994E06

P577

Q33369363-F6E7C6D5-702D-4D7E-8945-2E9269535751

P698

Q33369363-6D5A5205-486D-4735-AAE8-D3F2F92C583A

P921

Q33369363-A18ECF54-885E-4A8A-B4FF-8A35F7CDF04A

P356

JCO.2005.02.4448

P1433

Journal of Clinical Oncology

P1476

Ixabepilone (epothilone B anal ...... st Oncology Group trial S0111.

@en

P2093

A Dimitrios Colevas

http://www.w3.org/2001/XMLSchema#string

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Maha Hussain

http://www.w3.org/2001/XMLSchema#string

Primo N Lara

http://www.w3.org/2001/XMLSchema#string

Ulka N Vaishampayan

http://www.w3.org/2001/XMLSchema#string

Wael A Sakr

http://www.w3.org/2001/XMLSchema#string

P304

8724-8729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.4448

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16314632

http://www.w3.org/2001/XMLSchema#string

P921